newsfilter
← Latest News
Business Wire·

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results

– Third Quarter 2022 Total Revenue of $36.0 Million; QINLOCK® Net Product Revenue Increases 49% to $32.3 Million Compared to Third Quarter 2021 – – Presented Updated Results from Phase 1/2 Study of Vimseltinib in